异噁唑并[4,5-b]吡啶-3(2H)-酮 | 122019-40-3

• 分子结构分类: 有机化合物 - 有机杂环化合物 - 异恶唑并吡啶类
• 中文名称: 异噁唑并[4,5-b]吡啶-3(2H)-酮
• 中文别名: 异恶唑并[4,5-B]吡啶-3(2H)-酮
• 英文名称: isoxazolo<4,5-b>pyridin-3-ol
• 英文别名: Isoxazolo[4,5-b]pyridin-3(2H)-one；[1,2]oxazolo[4,5-b]pyridin-3-one
• CAS: 122019-40-3
• 化学式: C₆H₄N₂O₂
• 分子量: 136.11
• InChiKey: NZYHQGWJHXLVCA-UHFFFAOYSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  0.4
• 重原子数：
  10
• 可旋转键数：
  0
• 环数：
  2.0
• sp3杂化的碳原子比例：
  0.0
• 拓扑面积：
  51.2
• 氢给体数：
  1
• 氢受体数：
  3

安全信息

• 海关编码：
  2934999090

反应信息

• 作为产物：
  描述：

  3-羟基-2-吡啶甲酸 在 sodium hydroxide 、 氯化亚砜 、 盐酸羟胺 、 三乙胺 作用下， 以 四氢呋喃 、 乙醚 、 乙醇 、 水 为溶剂， 生成 异噁唑并[4,5-b]吡啶-3(2H)-酮
  参考文献：
  名称：

  Evaluation and synthesis of amino-hydroxy isoxazoles and pyrazoles as potential glycine agonists

  摘要：

  Except for structurally similar small amino acids, such as alanine, beta-alanine, and serine, compounds acting as glycine-receptor agonists are an unknown class of pharmacological agents. To investigate the potential of small, substituted heterocycles to act as glycine agonists, we have evaluated the similarities between glycine and a series of hydroxy- and amino-substituted pyrazoles and isoxazoles through complementary molecular modeling techniques. Using a "scorecard approach" to determine the overall similarity of projected agonist structures to glycine, we prioritized synthesis and subsequently prepared several novel derivatives. The biological activity of these compounds was compared to that of glycine by using a [3H]strychnine-mediated glycine receptor binding assay. Despite the close similarity in the calculated parameters when compared to glycine, no significant receptor-binding activity was observed for the targeted analogues. These results illustrate the structurally exacting nature of the glycine receptor.

  DOI：

  10.1021/jm00129a016

文献信息

• ACETIC ACID AMIDE DERIVATIVE HAVING INHIBITORY ACTIVITY ON ENDOTHELIAL LIPASE
  申请人：Shionogi & Co., Ltd.

  公开号：US20140288302A1

  公开（公告）日：2014-09-25

  A pharmaceutical composition including a compound of formula (I): its pharmaceutically acceptable salt, or a solvate thereof. Ring A is nitrogen-containing hetero ring, Ring A may be substituted with a substituent other than a group represented by formula: —C(R 1 R 2 )—C(═O)—NR 3 R 4 and a group represented by formula: —R 5 , a broken line represents presence or absence of a bond, Z is —NR 6 —, ═N—, —O—, or —S—, R 6 is halogen or substituted or unsubstituted alkyl, R 1 and R 2 are each independently hydrogen, halogen, hydroxy, cyano, nitro, carboxy or substituted or unsubstituted alkyl, R 3 is hydrogen or substituted or unsubstituted alkyl, R 4 is hydrogen or substituted or unsubstituted alkyl, R 3 and R 4 taken together with the adjacent nitrogen atom to which they are attached may form a substituted or unsubstituted ring, R 5 is hydrogen, halogen, hydroxy, cyano, nitro, carboxy, substituted or unsubstituted alkyl, substituted or unsubstituted alkenyl, or substituted or unsubstituted alkynyl.

  一种包括化合物(I)的制药组合物：其药学上可接受的盐或其溶剂合物。环A是含氮杂环，环A可以用除了公式所表示的基团之外的取代基团取代：—C(R1R2)—C(═O)—NR3R4和公式表示的基团：—R5，其中断线表示键的存在或不存在，Z是—NR6—，═N—，—O—或—S—，R6是卤素或取代或未取代的烷基，R1和R2各自独立地是氢、卤素、羟基、氰基、硝基、羧基或取代或未取代的烷基，R3是氢或取代或未取代的烷基，R4是氢或取代或未取代的烷基，R3和R4与它们所连接的相邻氮原子一起可以形成取代或未取代的环，R5是氢、卤素、羟基、氰基、硝基、羧基、取代或未取代的烷基、取代或未取代的烯基或取代或未取代的炔基。
• ACETIC ACID AMIDE DERIVATIVE HAVING INHIBITORY ACTIVITY ON VASCULAR ENDOTHELIAL LIPASE
  申请人：Shionogi & Co., Ltd.

  公开号：EP2351744A1

  公开（公告）日：2011-08-03

  Disclosed is a compound which is useful as an endothelial lipase inhibitor. A pharmaceutical composition having inhibitory activity on endothelial lipase comprising a compound represented by the formula: , its pharmaceutically acceptable salt, or a solvate thereof, wherein Ring A is nitrogen-containing hetero ring, Ring A may be substituted with a substituent other than a group represented by the formula: -C(R1R2)-C(=O)-NR3R4 and a group represented by the formula: -R5, a broken line represents the presence or the absence of a bond, Z is -NR6-, =N-, -O-, or -S-, R6 is halogen, substituted or unsubstituted alkyl or the like, R1 and R2 are each independently hydrogen, halogen, hydroxy, cyano, nitro, carboxy or substituted or unsubstituted alkyl, R3 is hydrogen or substituted or unsubstituted alkyl, R4 is hydrogen, substituted or unsubstituted alkyl or the like, R3 and R4 taken together with the adjacent nitrogen atom to which they are attached may form a substituted or unsubstituted ring, R5 is hydrogen, halogen, hydroxy, cyano, nitro, carboxy, substituted or unsubstituted alkyl, substituted or unsubstituted alkenyl, substituted or unsubstituted alkynyl or the like.

  本发明公开了一种可用作内皮脂肪酶抑制剂的化合物。一种对内皮脂肪酶具有抑制活性的药物组合物，包含一种由式表示的化合物： 、其药学上可接受的盐或其溶液、 其中 环 A 是含氮杂环、 环 A 可被除由式表示的基团以外的取代基取代：-C(R1R2)-C(＝O)-NR3R4和式中代表的基团以外的取代基取代：-R5, 断线表示存在或不存在键、 Z 是-NR6-、＝N-、-O-或-S-、 R6 是卤素、取代或未取代的烷基或类似物、 R1 和 R2 各自独立地是氢、卤素、羟基、氰基、硝基、羧基或取代或未取代的烷基、 R3 是氢、取代或未取代的烷基、 R4 是氢、取代或未取代的烷基或类似物、 R3 和 R4 与它们所连接的相邻氮原子一起可形成一个取代或未取代的环、 R5 是氢、卤素、羟基、氰基、硝基、羧基、取代或未取代的烷基、取代或未取代的烯基、取代或未取代的炔基或类似物。
• ISOXAZOLES
  申请人：SANKYO COMPANY LIMITED

  公开号：EP0779281B1

  公开（公告）日：2003-10-29
• US5965591A
  申请人：——

  公开号：US5965591A

  公开（公告）日：1999-10-12
• US6096771A
  申请人：——

  公开号：US6096771A

  公开（公告）日：2000-08-01